STAAR Surgical Q2 2026: Net Income $8.1M, China Sales Surge 888%
STAA sits 57% above its 52-week low of $15.585.
Summary
STAAR Surgical reported Q2 2026 net income of $8.1 million, up from a $16.8 million loss last year, driven by a surge in China sales. The company also disclosed ERP implementation challenges and confirmed Warren Foust as permanent CEO.
Key Events · Earnings and Guidance · STAA
-
Q2 2026 Net Income $8.1M
STAAR Surgical reported net income of $8.1 million ($0.16 diluted EPS) for Q2 2026, compared to a net loss of $16.8 million in Q2 2025. Net sales rose 111% to $93.5 million.
-
China Sales Surge 888%
China net sales reached $52.3 million in Q2 2026, up from $5.3 million in Q2 2025. China distributors now account for 56% of total net sales and 65% of trade receivables.
-
Gross Margin Improves to 74.5%
Gross margin increased to 74.5% from 74.0% year-over-year, driven by cost reduction initiatives, partially offset by tariffs on U.S.-manufactured products sold to China.
-
Cash Position Strengthens to $181.5M
Cash and investments available for sale increased to $181.5 million at July 3, 2026, up from $163.9 million at April 3, 2026. The company expects to continue generating cash.
Analysis · STAA · Industrial Applications And Services
STAAR Surgical delivered a strong Q2 2026 with net income of $8.1 million, a dramatic turnaround from the $16.8 million loss a year ago. The quarter was driven by explosive growth in China, where net sales jumped from $5.3 million to $52.3 million. Gross margin improved to 74.5%, and the company's cash position strengthened to $181.5 million. However, the company disclosed that its new ERP system caused operational challenges requiring manual intervention, with remediation expected in Q3 2026. The filing also confirms Warren Foust as permanent CEO and details performance-based stock options with stock price hurdles of $50, $75, and $100 per share.
At the time of this filing, STAA was trading at $24.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $15.59 to $35.87. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.